Last reviewed · How we verify
Tenofovir alafenamide/emtricitabine
Tenofovir alafenamide and emtricitabine are nucleotide/nucleoside reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA.
Tenofovir alafenamide and emtricitabine are nucleotide/nucleoside reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 pre-exposure prophylaxis (PrEP) in at-risk individuals.
At a glance
| Generic name | Tenofovir alafenamide/emtricitabine |
|---|---|
| Also known as | TAF, FTC |
| Sponsor | ViiV Healthcare |
| Drug class | Nucleotide/nucleoside reverse transcriptase inhibitor combination |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Tenofovir alafenamide (TAF) is a prodrug of tenofovir that achieves higher intracellular concentrations with lower systemic exposure compared to tenofovir disoproxil fumarate. Emtricitabine (FTC) is a cytidine analog that inhibits reverse transcriptase. Together, they prevent HIV from integrating into the host genome and establishing persistent infection.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
- HIV-1 pre-exposure prophylaxis (PrEP) in at-risk individuals
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
- Abnormal liver function tests
- Renal impairment (rare)
Key clinical trials
- Spotting Syphilis: A Dual Point-of-Care Syphilis Screening Initiative in a Low-Resource Healthcare Setting (NA)
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) (PHASE2, PHASE3)
- Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018) (PHASE3)
- Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1 (PHASE2, PHASE3)
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE: A Multi-Center, Single-Arm, Open-Label, Phase 4 Study Assessing the Safety and Efficacy of B/F/TAF in HIV-Positive Adults Returning to Care After Experiencing a Treatment Interruption of ≥12 Weeks (PHASE4)
- Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tenofovir alafenamide/emtricitabine CI brief — competitive landscape report
- Tenofovir alafenamide/emtricitabine updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI